Patents Examined by Joseph F. Murphy
  • Patent number: 6194162
    Abstract: The P2X receptor of ATP has been cloned and expressed by recombinant DNA technology, so the receptor can be prepared free from other ATP receptors. The P2X receptor enables antibodies to be prepared and is useful in screening compounds for use in a variety of diseases and conditions, including epilepsy, cognition, emesis, pain (especially migraine), asthma, peripheral vascular disease, hypertension, diseases of the immune system, irritable bowel syndrome and premature ejaculation.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: February 27, 2001
    Assignee: Glaxo Group Limited
    Inventors: Soledad Valera, Gary N Buell
  • Patent number: 6184358
    Abstract: The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen. Another aspect of the invention relates to isolated and/or recombinant nucleic acids encoding a mammalian (e.g., human) CXCR3 protein and variants thereof, including antisense nucleic acid, recombinant nucleic acid constructs, such as plasmids or retroviral vectors, comprising a nucleic acid which encodes a protein of the present invention or variant thereof, and to host cells comprising a nucleic acid or construct, useful in the production of recombinant proteins.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: February 6, 2001
    Assignees: Millennium Pharmaceuticals, Inc., Theodor-Kocher Institute
    Inventors: Marcel Loetscher, Bernhard Moser, Shixin Qin, Charles R. Mackay
  • Patent number: 6171550
    Abstract: A method for improving products such as toothpaste, shampoo, soap, detergent and lotions or creams by utilizing a water base for the product that is about 99% water, 0.68% cellulose and 0.32% emulsified food grade wax. Products produced with this water base will not decompose even though chemical preservatives is not included as an ingredient. The water base is formed by filtering hydrous cellulose pulp that is resistant to decomposition through a very fine filter. The hydrous cellulose pulp can be produced either by recycling waxed paper or thorough a process that begins with virgin vegetable constituents and wax. The filtrate, or water base can also be used in the horticultural field to prevent mold on plants and in physiology area to prevent the degradation of cells.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: January 9, 2001
    Assignee: Preservation Products, LLC
    Inventor: Bernard Bendiner
  • Patent number: 6159700
    Abstract: Human GPR14 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human GPR14 polypeptides and polynucleotides in the design of protocols for the treatment of ischemic coronary artery disease (angina and myocardial infarction); atherosclerosis; metabolic diseases (e.g. diabetes); CHF/myocardial dysfunction; arrhythmias; restenosis; hypertension; hypotension; pulmonary disease (hypertension, COPD, asthma); fibrotic vasculopathies (diabetes, SLE, AS, Reynaud's); cerebrovascular events (e.g. hemnorrhagic and ischemic stroke); neurogenic inflammation/migraine; hematopoictic disorders; ARDS; cancer; autoimmune diseases (e.g. HIV-1 and -2 infection and AIDS); gastrointestinal and genitourinary disturbances (e.g. ulcers) endocrine disorders; fibroproliferative disorders (e.g. psoriasis); inflammatory disease (e.g.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: December 12, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham plc, SB Laboratoires Pharmaceutiques
    Inventors: Nambi V Aiyar, Robert S Ames, Anne Romanic Arnold, Kamal Al-Barazanji, Derk J Bergsma, Jon Chambers, Stephen A Douglas, James J Foley, Bernard Gout, Nassirah Khandoudi, Henry M Sarau, Usman Shabon, Robert N Willette
  • Patent number: 6156523
    Abstract: The invention provides human serine/threonine protein kinases (HSTK) and polynucleotides which identify and encode HSTK. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HSTK.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: December 5, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Y. Tom Tang, Surya K. Goli, Neil C. Corley, Karl J. Guegler, Gina A. Gorgone, Jennifer L. Hillman
  • Patent number: 6140064
    Abstract: The present invention relates to methods of identifying ligands, and inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function, including methods in which host cells comprising a nucleic acid encoding a CXCR3 or variant thereof are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters. Inhibitors and promoters of receptor function can be used to modulate receptor activity, permitting selective inhibition of lymphocyte function, particularly of effector cells such as activated T lymphocytes and NK cells for therapeutic purposes.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: October 31, 2000
    Assignee: Theodor-Kocher Institute
    Inventors: Marcel Loetscher, Bernhard Moser
  • Patent number: 6133420
    Abstract: Human GPR14 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human GPR14 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: April 10, 1998
    Date of Patent: October 17, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham plc
    Inventors: Robert S. Ames, Jr., Henry M. Sarau, James J. Foley, Usman Shabon, Derk Bergsma, Jonathan K. Chambers
  • Patent number: 6087488
    Abstract: Novel genes in the erg subfamily of potassium channel proteins in humans are described. This family of proteins, and the genes encoding the proteins, are implicated in the development of long Q-T syndrome, a rare, but often fatal, cardiac arrhythmia.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: July 11, 2000
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Barry S. Ganetzky, Steven A. Titus